Human urotensin-II as a novel cardiovascular target: 'heart' of the matter or simply a fishy 'tail'?

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Current opinion in pharmacology (Print)

• Publication date

  2003-04-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/S1471-4892(03)00012-2PMID 12681238
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Structure-function analysis of urotensin II and its use in the construction of a ligand-receptor working model.

  2002cited by this paper
• High plasma concentrations of human urotensin II do not alter local or systemic hemodynamics in man.

  2002cited by this paper
• Plasma urotensin II in heart failure.

  2002cited by this paper
• Lysophosphatidylcholine potentiates the mitogenic effect of various vasoactive compounds on rabbit aortic smooth muscle cells.

  2002cited by this paper
• Plasma levels and cardiovascular gene expression of urotensin-II in human heart failure.

  2002cited by this paper
• Effects of human urotensin II in isolated vessels of various species; comparison with other vasoactive agents

  2002cited by this paper
• Localization of Urotensin-II Immunoreactivity in Normal Human Kidneys and Renal Carcinoma

  2002cited by this paper
• Discovery of the first nonpeptide agonist of the GPR14/urotensin-II receptor: 3-(4-chlorophenyl)-3-(2- (dimethylamino)ethyl)isochroman-1-one (AC-7954).

  2002cited by this paper
• Is urotensin‐II the new endothelin?

  2002cited by this paper
• Urotensin II evokes potent vasoconstriction in humans in vivo

  2002cited by this paper
• Identification of nonpeptidic urotensin II receptor antagonists by virtual screening based on a pharmacophore model derived from structure-activity relationships and nuclear magnetic resonance studies on urotensin II.

  2002cited by this paper
• Congestive heart failure and expression of myocardial urotensin II.

  2002cited by this paper
• Human urotensin II-induced aorta ring contractions are mediated by protein kinase C, tyrosine kinases and Rho-kinase: inhibition by somatostatin receptor antagonists.

  2002cited by this paper
• Pharmacological characterization of SB‐710411 (Cpa‐c[D‐Cys‐Pal‐D‐Trp‐Lys‐Val‐Cys]‐Cpa‐amide), a novel peptidic urotensin‐II receptor antagonist

  2002cited by this paper
• A new, potent urotensin II receptor peptide agonist containing a Pen residue at the disulfide bridge.

  2002cited by this paper
• Design, synthesis, conformational analysis, and biological studies of urotensin-II lactam analogues.

  2002cited by this paper
• Co-expression of urotensin II and its receptor (GPR14) in human cardiovascular and renal tissues

  2001cited by this paper
• Effects of Urotensin II in Human Arteries and Veins of Varying Caliber

  2001cited by this paper
• Increased urotensin II plasma levels in patients with cirrhosis and portal hypertension.

  2001cited by this paper
• Urotensin II induces hypertrophic responses in cultured cardiomyocytes from neonatal rats

  2001cited by this paper
• Depressor and regionally‐selective vasodilator effects of human and rat urotensin II in conscious rats

  2001cited by this paper
• Role of urotensin II in patients on dialysis.

  2001cited by this paper
• Expression of urotensin II and urotensin II receptor mRNAs in various human tumor cell lines and secretion of urotensin II-like immunoreactivity by SW-13 adrenocortical carcinoma cells.

  2001cited by this paper
• Human Urotensin II–Induced Contraction and Arterial Smooth Muscle Cell Proliferation Are Mediated by RhoA and Rho-Kinase

  2001cited by this paper
• Cardiostimulant effects of urotensin‐II in human heart in vitro

  2001cited by this paper
• Comparison of the contractile responses of human coronary bypass grafts and monkey arteries to human urotensin‐II

  2001cited by this paper
• Human urotensin-II, the most potent mammalian vasoconstrictor identified to date, as a therapeutic target for the management of cardiovascular disease.

  2000cited by this paper
• Differential vasoconstrictor activity of human urotensin‐II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey

  2000cited by this paper
• Novel urotensin II (UII) antagonists point to multiple receptor involvement in UII bioactivity

  2000cited by this paper
• Contractile responses to human urotensin‐II in rat and human pulmonary arteries: effect of endothelial factors and chronic hypoxia in the rat

  2000cited by this paper
• Orphan‐receptor ligand human urotensin II: receptor localization in human tissues and comparison of vasoconstrictor responses with endothelin‐1

  2000cited by this paper
• Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14

  1999cited by this paper
• Functional receptors for fish neuropeptide urotensin II in major rat arteries.

  1988cited by this paper
• Textbook of Pharmacology.

  1980cited by this paper

• Investigation of Urotensin II expression in placenta and umbilical cord in pregnancies with intrauterine growth restriction by histological and biochemical methods.

  2024cites this paper
• Discovery of a Potent and Orally Bioavailable Zwitterionic Series of Selective Estrogen Receptor Degrader-Antagonists.

  2023cites this paper
• Identification of novel Urotensin-II receptor antagonists with potent inhibition of U-II induced pressor response in mice.

  2020cites this paper
• Novel insights into the role of urotensin II in cardiovascular disease.

  2019cites this paper
• Plasma urotensin-2 as a marker for menstrual irregularities in women: a clinical study

  2019cites this paper
• A novel urotensin II receptor antagonist, KR‐36996, improved cardiac function and attenuated cardiac hypertrophy in experimental heart failure

  2017cites this paper
• G Protein-coupled Receptor Biased Agonism.

  2016cites this paper
• Accurate quantification of modified cyclic peptides without the need for authentic standards.

  2016cites this paper
• Effect of Different Peptides

  2015cites this paper
• Urotensin II as a novel marker for portal hypertension and bleeding varices: an Egyptian survey

  2015cites this paper
• Biased signaling regulates the pleiotropic effects of the urotensin II receptor to modulate its cellular behaviors

  2014cites this paper
• Urantide Conformation and Interaction with the Urotensin‐II Receptor

  2014cites this paper
• Lead optimization of P5U and urantide: discovery of novel potent ligands at the urotensin-II receptor.

  2014cites this paper
• Predicted Ligands for the Human Urotensin‐II G Protein‐Coupled Receptor with Some Experimental Validation

  2014cites this paper
• Identification of transmembrane domain 3, 4 & 5 residues that contribute to the formation of the ligand-binding pocket of the urotensin-II receptor.

  2013cites this paper
• Validation of LC-MS/MS Method for Determination of Bivalirudin in Human Plasma: Application to a Pharmacokinetic Study

  2013cites this paper
• New insight into the binding mode of peptides at urotensin‐II receptor by Trp‐constrained analogues of P5U and urantide

  2013cites this paper
• Immunomodulatory role of urotensins in teleost Channa punctatus.

  2011cites this paper
• Potential Clinical Implications of the Urotensin II Receptor Antagonists

  2011influential citation
• In Vitro Manipulation of Urotensin-II Receptor Expression: Implications of Receptor Density on Ligand Efficacy

  2011influential citation
• The Role of Translational Medicine and Predictive Biomarkers in the Development of Novel, Innovative Treatments for the Management of Chronic Heart Failure: A Pharmaceutical Industry Perspective

  2010cites this paper
• Increased expression of urotensin II and GPR14 in patients with cirrhosis and portal hypertension.

  2010cites this paper
• Human urotensin II in internal mammary and radial arteries of patients undergoing coronary surgery.

  2010cites this paper
• Prediction of the Three‐Dimensional Structure for the Rat Urotensin II Receptor, and Comparison of the Antagonist Binding Sites and Binding Selectivity between Human and Rat Receptors from Atomistic Simulations

  2010cites this paper
• rotein expression of urotensin II , urotensin-related peptide and their eceptor in the lungs of patients with lymphangioleiomyomatosis

  2010cites this paper
• Urotensin II alters vascular reactivity in animals subjected to volume overload.

  2010cites this paper
• The pro-angiogenic activity of urotensin-II on human vascular endothelial cells involves ERK1/2 and PI3K signaling pathways.

  2010cites this paper
• Urotensin II Activates Sarcolemmal Na+/H+ Exchanger in Adult Rat Ventricular Myocytes

  2010cites this paper
• Pro-angiogenic activity of Urotensin-II on different human vascular endothelial cell populations.

  2009cites this paper
• New insight into the binding mode of peptide ligands at Urotensin-II receptor: structure-activity relationships study on P5U and urantide.

  2009cites this paper
• Increased plasma urotensin-II and carotid atherosclerosis are associated with vascular dementia.

  2009cites this paper
• Human urotensin II promotes hypertension and atherosclerotic cardiovascular diseases.

  2009cites this paper
• Elevated expression of urotensin II and its receptor in great artery of type 2 diabetes and its significance.

  2009cites this paper
• Pharmacokinetics and Pharmacodynamics of the Urotensin‐II Receptor Antagonist Palosuran in Healthy Male Subjects

  2009cites this paper
• Identification of transmembrane domain 6 & 7 residues that contribute to the binding pocket of the urotensin II receptor.

  2009cites this paper
• Identification of new agonists of urotensin-II from a cyclic peptide library.

  2009cites this paper
• Cardiorenovascular effects of urotensin II and the relevance of the UT receptor.

  2008cites this paper
• Role of urotensin II in atherosclerotic cardiovascular diseases.

  2008cites this paper
• Increased plasma urotensin-II levels are associated with diabetic retinopathy and carotid atherosclerosis in Type 2 diabetes.

  2008cites this paper
• Effects of urotensin-II on cerebral blood flow and ischemia in anesthetized rats.

  2008cites this paper
• Evidence for endogenous urotensin-II as an inhibitor of insulin secretion. Study in the perfused rat pancreas.

  2008cites this paper
• Biological properties and functional determinants of the urotensin II receptor.

  2008cites this paper
• Strategies to optimize renoprotective therapy in proteinuric renal patients

  2008cites this paper
• Synthèse de ligands du récepteur de l'Urotensine II et des récepteurs de la Mélatonine : composés à noyau pyrido[2,3-d]pyrimidine ou imidazo[1,2-a]pyridine

  2008cites this paper
• Behavioral actions of urotensin-II.

  2008cites this paper
• Effect of the urotensin receptor antagonist palosuran on albuminuria in hypertensive patients with type 2 diabetic nephropathy: results from the PROLONG proof-of-concept study

  2008cites this paper
• Cardiovascular Activity

  2008cites this paper
• Role of urotensin II and its receptor in health and disease

  2007cites this paper
• Photolabelling the urotensin II receptor reveals distinct agonist- and partial-agonist-binding sites.

  2007cites this paper
• Resonance scattering method for the ultrasensitive determination of peptides using semiconductor nanocrystals.

  2007cites this paper
• Fluorescence for the ultrasensitive detection of peptides with functionalized nano-ZnS.

  2007cites this paper
• Urotensin-II in the lung: A matter for vascular remodelling and pulmonary hypertension?

  2007cites this paper
• Therapeutic potential of blockade of the Urotensin II system in systemic hypertension

  2007cites this paper
• Does cigarette smoking increase plasma urotensin II concentrations?

  2007cites this paper
• Urotensin II: from osmoregulation in fish to cardiovascular regulation in man.

  2007cites this paper
• Urotensin II and Urotensin II–Related Peptide

  2006cites this paper
• Human Urotensin II as a Link between Hypertension and Coronary Artery Disease

  2006cites this paper
• Urotensin-II levels in acute coronary syndromes.

  2006cites this paper
• Vascular contractile effect of urotensin II in young and aged rats: influence of aging and contribution of endothelial nitric oxide.

  2006cites this paper
• The etiology of hypertension in the metabolic syndrome part three: the regulation and dysregulation of blood pressure.

  2006cites this paper
• Urotensin-II receptor antagonists.

  2006cites this paper
• Urotensin-II expression in the mouse spinal cord.

  2006cites this paper
• Novel potent and efficacious nonpeptidic urotensin II receptor agonists.

  2006cites this paper
• The peptidic urotensin‐II receptor ligand GSK248451 possesses less intrinsic activity than the low‐efficacy partial agonists SB‐710411 and urantide in native mammalian tissues and recombinant cell systems

  2006cites this paper
• Cell and tissue responses of a range of Urotensin II analogs at cloned and native urotensin II receptors. Evidence for coupling promiscuity

  2006influential citation
• Signaling through NADPH oxidases

  2006cites this paper
• Human Urotensin-II Potentiates the Mitogenic Effect of Mildly Oxidized Low-Density Lipoprotein on Vascular Smooth Muscle Cells: Comparison with Other Vasoactive Agents and Hydrogen Peroxide

  2006cites this paper
• Regional heterogeneity in the haemodynamic responses to urotensin II infusion in relation to UT receptor localisation

  2006cites this paper
• The multifunctional fish gill: dominant site of gas exchange, osmoregulation, acid-base regulation, and excretion of nitrogenous waste.

  2005cites this paper
• Involvement of a cytoplasmic-tail serine cluster in urotensin II receptor internalization.

  2005cites this paper
• Nonpeptidic urotensin‐II receptor antagonists I: in vitro pharmacological characterization of SB‐706375

  2005cites this paper
• Urotensin-II receptor ligands. From agonist to antagonist activity.

  2005cites this paper
• Development and pharmacological characterization of "caged" urotensin II analogs.

  2005cites this paper
• Structure–activity relationship study on human urotensin II

  2005cites this paper
• Effects of pre-eclampsia on maternal plasma, cerebrospinal fluid, and umbilical cord urotensin II concentrations: a pilot study.

  2005cites this paper
• Arrestin-Independent Internalization and Recycling of the Urotensin Receptor Contribute to Long-Lasting Urotensin II–Mediated Vasoconstriction

  2005cites this paper
• Human Urotensin II Is a Novel Activator of NADPH Oxidase in Human Pulmonary Artery Smooth Muscle Cells

  2005cites this paper
• Role of prostaglandins in urotensin II-induced vasodilatation in the coronary arteries of aged rats.

  2005cites this paper
• Urotensin II: evidence for cardiac, hepatic and renal production.

  2005cites this paper
• Urotensin II acts as a modulator of mesopontine cholinergic neurons.

  2005cites this paper
• Increased expression of urotensin II and urotensin II receptor in human diabetic nephropathy.

  2004cites this paper
• Unraveling the active conformation of urotensin II.

  2004cites this paper
• Urotensin II and cardiovascular diseases.

  2004cites this paper
• Urotensin II: the old kid in town.

  2004cites this paper
• Central effects of native urotensin II on motor activity, ventilatory movements, and heart rate in the trout Oncorhynchus mykiss.

  2004cites this paper
• Human urotensin-II enhances plasma extravasation in specific vascular districts in Wistar rats.

  2004cites this paper
• Identification and pharmacological characterization of native, functional human urotensin‐II receptors in rhabdomyosarcoma cell lines

  2004cites this paper
• Differential levels of "urotensin-II-like" activity determined by radio-receptor and radioimmuno-assays.

  2004cites this paper
• Differential Effect of Urotensin II on Vascular Tone in Normal Subjects and Patients With Chronic Heart Failure

  2004cites this paper
• Identification of novel adrenomedullin in mammals: a potent cardiovascular and renal regulator

  2004cites this paper
• Biochemical characterization and immunohistochemical localization of urotensin II in the human brainstem and spinal cord

  2004cites this paper
• Emerging roles of urotensin-II in cardiovascular disease.

  2004cites this paper
• Differential agonistic and antagonistic effects of the urotensin-II ligand SB-710411 at rodent and primate UT receptors.

  2004cites this paper
• Urotensin-II: a novel systemic hypertensive factor in the cat

  2004cites this paper
• Bolus injection of human UII in conscious rats evokes a biphasic haemodynamic response

  2004cites this paper
• Urotensin II in the cardiovascular system.

  2004cites this paper
• Urotensin‐II receptor peptide agonists

  2004cites this paper
• Analytical procedures for quantification of peptides in pharmaceutical research by liquid chromatography–mass spectrometry

  2004cites this paper
• From 'gills to pills': urotensin-II as a regulator of mammalian cardiorenal function.

  2004cites this paper
• Urantide: an ultrapotent urotensin II antagonist peptide in the rat aorta

  2003influential citation